Fig. 1: Basic characterization of cancer-related genes from AIS to advanced lung adenocarcinomas.

a Representative H&E images of Early-Ad cases with Noguchi classification. We analyzed 9, 19, 20 of Noguchi type A, B and C Early-Ad cases, respectively, in this study. Images show representative examples of tissue regions for each histological subtype, which were annotated by the pathologists. b The somatic mutation status of cancer-related genes. Point mutation and SV statuses of oncogenes, tumor-suppressor genes and other known mutated genes are shown in each case. c The proportion of cases with EGFR hotspot mutations (e.g., L858R, exon 18/19 deletions and exon 20 insertions), TP53 mutations, SMARCA4 and SMARCA2 mutations, and RBM10 mutations in the corresponding AIS, MIA/Lepidic-Ad and Advanced-Ad cases. When comparing Early-Ad and Advanced -Ad cases, the p-values are indicated by asterisks, **p < 0.05, ***p < 0.005. n.s.: not significant (p ≥ 0.05). The p-values were calculated by Fisher’s exact test (two-sided, no multiple comparison adjustments). d CNV status of cancer-related genes. Copy number gains for the representative oncogenes and genes frequently reported with amplifications in lung cancers (upper panel). Copy number losses are also shown for the representative tumor suppressor genes (lower panel). e Copy number profiles of representative cases. Cancer-related genes affected by copy number aberrations are shown in the inset. f Aberrant events in CDKN2A region in each case (left). Proportion of cases with CDKN2A aberrations in the corresponding AIS, MIA/Lepidic-Ad, and Advanced-Ad cases (right). CN copy number. Whole-gene deletion (>1): whole-gene deletions detected with ≥2 deletion breakpoint pairs, which possibly indicates homozygous deletions. Source data are provided as a Source Data file for (b).